Metjenta 50/850 And 50/1 000 50/850 mg, 50/1 000 mg FC tablets.
PDF Leaflet Revision Date: Not revised yet.
Clinical Summary
Quick overview from the medicine insert
Indication
Adjunct to diet and exercise for glycaemic control in type 2 diabetes.
Dosage (summary)
Starting dose based on current regimen; usual starting dose is 50 mg sitagliptin twice daily.
Special Populations
- Renal impairment
- Hepatic impairment
- Elderly patients
Pregnancy & Breastfeeding
Not recommended in pregnancy or breastfeeding.
Key Drug Interactions
- Alcohol
- Iodinated contrast agents
- NSAIDs
Contraindications
- Hypersensitivity to components
- Renal disease
- Hepatic impairment
- Acute metabolic acidosis
- Diabetic pre-coma
Common side effects
- Hypoglycaemia
- Nausea
- Diarrhoea
- Headache
- Metallic taste
Counselling Points
- Monitor renal function regularly.
- Avoid excessive alcohol intake.
- Report symptoms of pancreatitis.
Serious warnings
- Risk of lactic acidosis
- Acute pancreatitis
- Serious hypersensitivity reactions
Important Disclaimer
The Metjenta 50/850 And 50/1 000 50/850 mg, 50/1 000 mg FC tablets. professional information leaflet below is the property of Elttab Pharmaceuticals Cc and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
